MX9308191A - Antagonistas de endotelina. - Google Patents

Antagonistas de endotelina.

Info

Publication number
MX9308191A
MX9308191A MX9308191A MX9308191A MX9308191A MX 9308191 A MX9308191 A MX 9308191A MX 9308191 A MX9308191 A MX 9308191A MX 9308191 A MX9308191 A MX 9308191A MX 9308191 A MX9308191 A MX 9308191A
Authority
MX
Mexico
Prior art keywords
disease
ischemic
hypertension
endothelin
antagonists
Prior art date
Application number
MX9308191A
Other languages
English (en)
Inventor
John Xiaogiang He
Michael Douglas Taylor
Wayne Livingston Cody
Patricia De Pue
Annette Marian Doherty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9308191A publication Critical patent/MX9308191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen antagonistas novedosos de endotelina, así como métodos para la preparación y las composiciones farmacéuticas de los mismos, que son útiles para tratar niveles elevados de endotelina, falla renal aguda y crónica, hipertensión, infarto al miocardio, desórdenes metabólicos, endocrinológicos y neurológicos, insuficiencia cardiaca congestiva, choque endotóxico, hemorragia subaracnoidea, arritmias, asma, preeclamsia, enfermedad de Reynaud, restenosis o angioplastia coronaria traslumimal percutánea, angina, cáncer, hipertensión pulmonar, enfermedad isquémica, daño a la mucosa gástrica, enfermedad de intestino isquémico y diabetes.
MX9308191A 1992-12-21 1993-12-17 Antagonistas de endotelina. MX9308191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,480 US5382569A (en) 1991-05-16 1992-12-21 Endotherlin antagonists

Publications (1)

Publication Number Publication Date
MX9308191A true MX9308191A (es) 1994-06-30

Family

ID=25541864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9308191A MX9308191A (es) 1992-12-21 1993-12-17 Antagonistas de endotelina.

Country Status (7)

Country Link
US (3) US5382569A (es)
EP (1) EP0675902A1 (es)
JP (1) JP3494649B2 (es)
AU (1) AU679712B2 (es)
CA (1) CA2146874A1 (es)
MX (1) MX9308191A (es)
WO (1) WO1994014843A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
GB9116925D0 (en) * 1991-08-06 1991-09-18 Antisoma Ltd Novel reagent for tumour imaging and therapy
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
GB9300048D0 (en) * 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1995000546A1 (fr) * 1993-06-25 1995-01-05 Kyowa Hakko Kogyo Co., Ltd. Peptide a effet antagoniste de l'endotheline
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US5786335A (en) * 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU2807197A (en) * 1996-05-16 1997-12-05 Warner-Lambert Company Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
AU756136B2 (en) * 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
WO1999037669A1 (en) * 1998-01-22 1999-07-29 Regents Of The University Of Minnesota PEPTIDES WITH β1 INTEGRIN SUBUNIT DEPENDENT CELL ADHESION MODULATING ACTIVITY
US6849712B1 (en) 1998-01-22 2005-02-01 Regents Of The University Of Minnesota Peptides with β1 integrin subunit dependent cell adhesion modulating activity
AU758353B2 (en) 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
EP1196186B1 (en) * 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
ATE286051T1 (de) 1999-12-31 2005-01-15 Encysive Pharmaceuticals Inc Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren
ATE440139T1 (de) 2000-02-11 2009-09-15 Genentech Inc Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003087157A2 (en) * 2002-04-12 2003-10-23 Pharmacia Corporation Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same
US7118549B2 (en) * 2003-10-31 2006-10-10 Codman & Shurtleff, Inc. Shunt system including a flow control device for controlling the flow of cerebrospinal fluid out of a brain ventricle
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
SG184755A1 (en) 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MX2008000874A (es) 2005-07-19 2008-04-04 Population Council Inc Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
ES2621018T3 (es) 2007-02-19 2017-06-30 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
MX2012006877A (es) * 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
CN107362171A (zh) 2011-04-15 2017-11-21 海洋聚合物技术公司 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病
TWI577697B (zh) * 2013-11-28 2017-04-11 國立清華大學 耐高鹽及抗蛋白之抗菌胜肽及其製造方法
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE90108T1 (de) * 1987-10-09 1993-06-15 Takeda Chemical Industries Ltd Vasokonstriktor-peptid.
CA2032559C (en) * 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
JP3294610B2 (ja) * 1991-05-16 2002-06-24 ワーナー−ランバート・コンパニー エンドセリン拮抗剤
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
FR2687155B1 (fr) * 1992-02-12 1995-05-19 Roussel Uclaf Nouveaux derives hexapeptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
JPH07505890A (ja) * 1992-04-22 1995-06-29 ワーナー−ランバート・コンパニー エンドセリンアンタゴニスト

Also Published As

Publication number Publication date
US5641752A (en) 1997-06-24
US5773414A (en) 1998-06-30
JP3494649B2 (ja) 2004-02-09
AU679712B2 (en) 1997-07-10
US5382569A (en) 1995-01-17
WO1994014843A1 (en) 1994-07-07
CA2146874A1 (en) 1994-07-07
JPH08504823A (ja) 1996-05-28
EP0675902A1 (en) 1995-10-11
AU5828094A (en) 1994-07-19

Similar Documents

Publication Publication Date Title
MX9308191A (es) Antagonistas de endotelina.
KR960700992A (ko) 페녹시페닐아세트산 유도체(Phenoxyphenylacetic acid derivatives)
NO986090L (no) Fenylalaninderivater som integrininhibitorer
ATE195948T1 (de) Endothelinantagonisten
DK1054887T3 (da) Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister
CA2080705A1 (en) Substituted pyrimidines
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
RU92004368A (ru) Замещенные пиримидины, способ их получения, фармацевтическая композиция
YU50002A (sh) Supstituisani piperidini, lekovi koji sadrže ova jedinjenja i postupci za njihovu proizvodnju
PT1023267E (pt) Compostos de piridilo e composicoes farmaceuticas que os contem
EP0867508A3 (en) Olfactory receptor of the 7-transmembrane receptor family - OLRCC15 receptor
FI973380A (fi) Bentsotiatsiinidioksidit endoteliiniantagonisteina
PL368529A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ES2186734T3 (es) Quinazolinas como inhibidores de la enzima de conversion de la endotelina.
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
AR026925A1 (es) Nuevos derivados de azabiciclooctano utiles en el tratamiento de arritmias cardiacas
DE69715242D1 (de) Helium-neon anregbare retikulozitfarbstoffe erhältlich aus halolepidinen
EP0881289A3 (en) Novel 7TM receptor (H2CAA71)
DE69624829D1 (de) Thienopyrimidinderivate als endothelin antagonisten
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
IT8648749A0 (it) 8-azaxantine alchilaminoalchil o eterociclilalchil sostituite sul nucleo triazolico,loro sali fisiologi camente accettabili,loro composizioni farmaceutiche ad attivita' antibroncospastica e relativo procedimento di preparazione
WO2004052887A3 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2001010841A3 (de) Fluorenderivate als integrin inhibitoren
TH5052A (es)
TH5052EX (th) เฟนนอกซีเบนซิล-(ไดฮาโลไดเมทธิลไซโคล โปรปิลเมทธิล)ฮีเธอร์ที่ถูกแทนที่